From Anti-HER-2 to Anti-HER-2-CAR-T Cells: An Evolutionary Immunotherapy Approach for Gastric Cancer

Current Therapeutic modalities provide no survival advantage to gastric cancer (GC) patients. Targeting the human epidermal growth factor receptor-2 (HER-2) is a viable therapeutic strategy against advanced HER-2 positive GC. Antibody-drug conjugates, small-molecule tyrosine kinase inhibitors (TKIs)...

Descripción completa

Detalles Bibliográficos
Autores principales: Sun, Jiangang, Li, Xiaojing, Chen, Peng, Gao, Yongshun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9304417/
https://www.ncbi.nlm.nih.gov/pubmed/35873388
http://dx.doi.org/10.2147/JIR.S368138

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9304417/
https://www.ncbi.nlm.nih.gov/pubmed/35873388
http://dx.doi.org/10.2147/JIR.S368138

Ejemplares similares